JLPC(SH:600513) Sou Hu Cai Jing·2025-08-04 07:29Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. has shown a significant increase in stock price and trading volume, indicating positive market sentiment despite a decline in net profit [1]. Financial Performance - As of Q1 2025, the company reported total revenue of 628 million yuan, representing a year-on-year growth of 18.78% [1]. - The net profit attributable to shareholders was 23.06 million yuan, a decrease of 29.15% year-on-year [1]. - The non-recurring net profit was 22.15 million yuan, down 27.95% year-on-year [1]. - The current ratio is 1.173, the quick ratio is 0.786, and the debt-to-asset ratio stands at 50.71% [1]. Market Activity - On August 4, 2025, the stock closed at 20.82 yuan, up 9.98%, with a turnover rate of 21.76% and a trading volume of 621,200 hands, amounting to a transaction value of 1.203 billion yuan [1]. - The net inflow of main funds was 160 million yuan, accounting for 13.28% of the transaction value, with large orders contributing 132 million yuan [1]. Company Background - Jiangsu Lianhuan Pharmaceutical Co., Ltd. was established in 2000 and is located in Yangzhou, primarily engaged in the pharmaceutical manufacturing industry [2]. - The company has a registered capital of 2.854 billion yuan and a paid-in capital of 40 million yuan [1][2]. - The legal representative of the company is Qian Zhenhua [1]. Investment and Intellectual Property - The company has made investments in 13 enterprises and participated in 5,000 bidding projects [2]. - It holds 46 trademark registrations and 240 patent applications, along with 559 administrative licenses [2].